Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that TOVALT ODT (zolpidem tartrate) orally disintegrating tablets, 5 milligrams (mg) and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for zolpidem tartrate, orally disintegrating tablets, 5 mg and 10 mg, if all other legal and regulatory requirements are met.
What this item does
The short version, using the agency's own summary text.
The Food and Drug Administration (FDA, Agency, or we) has determined that TOVALT ODT (zolpidem tartrate) orally disintegrating tablets, 5 milligrams (mg) and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for zolpidem tartrate, orally disintegrating tablets, 5 mg and 10 mg, if all other legal and regulatory requirements are met.
Notice.
Important dates
The dates that matter most for this item.
Published
July 9, 2026
Who published it
The agencies listed in the official filing.